mdnacb

ODAC Member Raises Concerns About Dendreon's Provenge

In reply to PharmaTracker's Blog:
Since an advisory committee voted strongly in favor of Provenge, Dendreon’s (DNDN) shares have increased to almost 300% from its lows of late. Sending Shorts into an all out War on Dendreon. Posting and placing false news reports which later were forced to be retracted.
Based on the Advisory Commitee's positive decisions for Provenge: Safety a 17-0 "Yes Vote" and on Efficacy a "Yes Vote" of 13-4 ,the FDA rarely goes against its advisory committee’s opinion, I am looking forward to seeing an Approval from the FDA on Provenge.
The key for cancer patients is survival and quality of life. Provenge is being tested in very sick cancer patients with positive results and for these cancer patients survival is as important as efficacy. There are many doubters who will twist and tweek the truth of Provenge saying it failed to meet its primary endpoints , a point of which will be used in an attempt to continue to short the stock.
I have had to stand on the sidelines and watch many of my family die from cancer and be tortured by Chemo. My elder Brother passed just over a year ago, Two Aunts less than a year ago(one resided with me and refused chemo having seen what it had done to other family members), My Sisters, Identical Twins died from similar cancers, one at the age of thirty and the other at Forty, Another Aunt, Three Uncles and my father to cancer related complications.
Now science is moving toward a New revolutionary way of Treating and Fighting cancer. Some of The Old Guards of Chemo-Mentality will have great difficulty moving away from their safety blanket(Chemo) and towards the New Immunotherapies coming into Mainstream Medicine. I can only assume based on Dr. Schers letter that he is holding on to his "Safety Blanket".

Disclosure: Author has a long position in DNDN and CELG